{
    "clinical_study": {
        "@rank": "119229", 
        "arm_group": [
            {
                "arm_group_label": "Caplresa Patient", 
                "description": "All patients treated with Caprelsa in Canada and participating in the restricted distribution programme."
            }, 
            {
                "arm_group_label": "Caplresa Prescriber", 
                "description": "All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada."
            }
        ], 
        "brief_summary": {
            "textblock": "Effectiveness of risk minimisation interventions for vandetanib in Canada"
        }, 
        "brief_title": "Vandetanib Risk Minimisation Effectiveness", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Medullary Thyroid Cancer", 
        "condition_browse": {
            "mesh_term": "Thyroid Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "As part of the new drug approval process in Canada, AstraZeneca has committed to Health\n      Canada to conduct a Drug Utilization Study among patients recently treated with CAPRELSA\n      (vandetanib) and a Knowledge and Understanding Survey among the prescribing physicians to\n      determine whether the product monograph, communication plan, and educational material\n      developed by AstraZeneca Canada for vandetanib are adequate to provide knowledge about the\n      potential risks associated with this product, and if other medications taken concomitantly\n      with vandetanib  are managed adequately."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - N/A (all patients taking Caprelsa and all prescribers will be contacted for\n        participation).\n\n        Exclusion Criteria: - N/A"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Convenience sample for patients and physicians"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757470", 
            "org_study_id": "D4200L00059"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "effectiveness of risk mitigation,", 
            "knowledge and understanding survey,", 
            "drug utilisation study,", 
            "post marketing committments"
        ], 
        "lastchanged_date": "July 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "2", 
        "official_title": "Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada", 
        "overall_official": {
            "affiliation": "Universit\u00e9 de Montr\u00e9al", 
            "last_name": "Yola Moride, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "QT prolongation/Torsades de Pointes, diarrhea, rash and other skin reactions- adequate or inadequate for each safety issue (defined by correct response).", 
                "measure": "Knowledge and Understanding Survey: Knowledge of the key safety issues pertaining to vandetanib", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Discontinuation, interruption, continuous", 
                "measure": "Drug Utilisation Study: Use of vandetanib - duration of treatment at baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Discontinuation, interruption, continuous", 
                "measure": "Drug Utilisation Study: Use of vandetanib - duration of treatment at 3 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 3 months"
            }, 
            {
                "description": "Discontinuation, interruption, continuous", 
                "measure": "Drug Utilisation Study: Use of vandetanib - duration of treatment at 6 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 6 months"
            }, 
            {
                "description": "Discontinuation, interruption, continuous", 
                "measure": "Drug Utilisation Study: Use of vandetanib - duration of treatment at 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 months"
            }, 
            {
                "measure": "Drug Utilisation Study: Use of vandetanib - dosage at baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline"
            }, 
            {
                "measure": "Drug Utilisation Study: Use of vandetanib - dosage at 3 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 3 months"
            }, 
            {
                "measure": "Drug Utilisation Study: Use of vandetanib - dosage at 6 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 6 months"
            }, 
            {
                "measure": "Drug Utilisation Study: Use of vandetanib - dosage at 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 months"
            }, 
            {
                "description": "Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs", 
                "measure": "Drug Utilisation Study: Concomitant use of QT-prolonging drugs at baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs", 
                "measure": "Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 3 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 3 months"
            }, 
            {
                "description": "Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs", 
                "measure": "Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 6 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 6 months"
            }, 
            {
                "description": "Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs", 
                "measure": "Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "At 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Main geographical location, average days devoted to patient care, total number of medullary thyroid cancer patients followed up to date.", 
                "measure": "Knowledge and Understanding Survey: Practice characteristics", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Participation in a trial on vandetanib, giving CME conferences, member of a data safety monitoring board.", 
                "measure": "Knowledge and Understanding Survey: Previous exposure to vandetanib safety concerns other than product monograph or mandatory online training", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Product monograph, online training, Dear Healthcare Professional letter sent by AstraZeneca, company's sales forces, continuing medical education, conferen.", 
                "measure": "Knowledge and Understanding Survey: Sources of information on key safety messages for vandetanib", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "Yolarx Consultants, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}